Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novelix Pharmaceuticals has exclusively licensed the rights to a group of innovative new cancer therapeutics from the University of Southern California.
Subscribe to our email newsletter
The lead compound, named NVX-144, is part of Novelix’ pipeline of first-in-class small molecule targeted drugs for cancers resistant to standard treatment. Based on preclinical data, Novelix anticipates that NVX-144 will be the first product in its portfolio to enter clinical development in late 2006.
“NVX-144 is unique among anticancer drugs in that it potently induces the anticancer gene IL-24. This causes tumor cells to self-destruct, while sparing normal tissues. IL-24 is a compelling target for oncology drug development,” said Dr Burkhard Jansen, CEO and co-founder of Novelix.
Novelix’ chairman Dr Timothy Triche added that the compound showed evidence of the safety and efficacy characteristics needed for rapid clinical development.
Novelix Pharmaceuticals is a biotechnology company committed to developing first-in-class targeted small molecules for cancer therapy. The company has currently selected four compounds for development.